1. Aghajanian C., Finkler N.J., Rutherford T., Smith D.A., Yi J., Parmar H., Nycum L.R., Sovak M.A.: OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 2011; 29 (Suppl.; Abstr. 5007)
2. Alberts D., Liu Y., Hannigan E.V., O’ Toole R., Williams S.D., Young J.A., Franklin E.W., Clarke-Pearson D.L., Malviya V.K., DuBeshter B., Adelson M.D., Hoskins W.J.: Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer. N Engl J Med 1996; 335:1950-1955
3. Allen D.G., Heintz A.P.M., Touw F.W.M.M.: A meta-analysis of residual disease and survival in stage III and IV carcinoma on the ovary. Eur J Gynaecol Oncol 1995; 16:349-356
4. Ameye L., Valentin L., Testa A.C., Van H.C., Domali E., Van H.S., Vergote I., Bourne T., and Timmerman D.: A scoring system to differentiate malignant from benign masses in specific ultrasound-based subgroups of adnexal tumors. Ultrasound Obstet Gynecol 2008; 33:92-101
5. Arits A.H., Stoot J.E., Botterweck A.A., Roumen F.J., Voogd A.C.: Preoperative serum CA-125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18:621-628
6. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland .LJ., Walker J.L., Burger R.A.; and the Gynecologic Oncology G.: Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. N Engl J Med 2006; 354:34-43
7. Ataseven H., Ozturk Z.A., Arhan M., Yuksel O., Koklu S., Ibis M., Basar O., Yilmaz F.M., Yuksel I.: Cancer antigen 125 levels in inflammatory bowel diseases. J Clin Lab Anal 2009: 23 (4):244-248
8. Åvall-Lundqvist E., Wimberger P., Gladieff L., Gebski V., Huober J.B., Floquet A., Fitzharris B., Zeimet A.G., Heywood M., Schmalfeldt B.: Pegylated liposomal doxorubicin (PLD)-carboplatin (C) (C-D) vs. paclitaxel-carboplatin (C-P) in relapsing sensitive ovarian cancer (OC): A 500-patient interim safety analysis of the CALYPSO GCIG Intergroup phase III study. J Clin Oncol 2008; 26 (May 20, Suppl.; Abstr. 5565)
9. Benedetti-Panici P., Maggioni A., Hacker N., Landoni F., Ackermann S., Campagnutta E., Tamussino K., Winter R., Pellegrino A., Greggi S., Angioli R., Manci N., Scambia G., Dell’Anna T., Fossati R., Floriani I., Rossi R.S., Grassi R., Favalli G., Raspagliesi F., Giannarelli D., Martella L., Mangioni C.: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial. J Natl Cancer Inst 2005; 97:560-566
10. Beral V.: Ovarian Cancer and Hormone Replacement Therapy in the Million Women Study. Lancet 2007; 9574:1703-1710
11. Bese T., Kösebay D., Kaleli S., Öz A.U., Demirkan F., Gezer A.: Appendectomy in the surgical staging of ovarian carcinoma. Int J Gynecol Obstet 1995; 53:249-252
12. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248-1259
13. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., Mannel R.S., Homesley H.D., Fowler J., Greer B.E., Boente M., Birrer M.J., Liang S.X.; Gynecologic Oncology Group: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473-83
14. Burks R.T., Sherman M.E., Kurman R.J.: Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996; 20:1319-1330
15. Carlson J.W., Miron A., Jarboe E.A., Parast M.M., Hirsch M.S., Lee Y., Muto M.G., Kindelberger D., Crum C.P.: Serous Tubal intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. JCO 2008; 26:4160-4165
16. Chan K.K., Tam K.F., Tse K.Y., Ngan H.Y.: The role of regular physical examination in the detection of ovarian cancer recurrence. Gynecol Oncol 2008; 110:158-161
17. Chu C.S. and Rubin S.C. Screening for ovarian cancer in the general population. Best Pract Res Clin Obstet Gynaecol 2006; 20:307-320
18. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., Fowler J.M.: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006; 102:134-139
19. Colombo N., Chiari S., Maggioni A., Bocciolone L., Torri V., Mangioni C.: Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy. Gynecol Oncol 1994; 55:47-51
20. Drapkin R., von Horsten H.H., Lin Y. et al.: Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65:2162-9
21. du Bois A., Pfisterer J, . Kellermann L.: Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland. Der Gynäkologe 2001; 34:1029-1040
22. du Bois A., Lück H.J., Meier W., Adams H.P., Möbus V., Costa S., Bauknecht T., Richter B., Warm M., Schröder W., Olbricht S., Nitz U., Jackisch C., Emons G., Wagner U., Kuhn W., Pfisterer J.: A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95:1320-1330
23. du Bois A., Harter P.: The role of surgery in advanced and recurrent ovarian cancer. Ann Oncol 2006; 17 Suppl 10:x235-240
24. Eisenkop S.M., Friedman R.L., Wang H.J.: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998; 69:103-108
25. Fehm T., Heller F., Krämer S., Häger W., Gebauer G.: Evaluation of CA 125, physical and radiological findings in followup of ovarian cancer patients. Anticancer Res 2005; 25:1551-1554
26. Fujita M., Enomoto T., Murata Y.: Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003; 202:97-99
27. Galgano M.T., Hampton G.M., Frierson H.F. Jr.: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19:847-53
28. Ghaemmaghami F., Karimi Z.M., Hamedi B.: High levels of CA125 (over 1,000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet 2007; 276 (5):559-561
29. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J.: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-22
30. Griffiths C.T., Parker L.M., Lee S., Finkler N.J.: The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term-results. Int J Gynecol Cancer 2002; 12:323-331
31. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., Elashoff R.M.: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61:413-420
32. Harter P., du Bois A.: The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. Curr Opin Oncol 2005; 17:505-514
33. Hauspy J., Covens A.: Cytoreductive surgery for recurrent ovarian cancer. Curr Opin Obstet Gynecol 2007; 19:15-21
34. Havrilesky L.J., Whitehead C.M., Rubatt J.M., Cheek R.L., Groelke J., He Q., Malinowski D.P., Fischer T.J., Berchuck A.: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008; 110 (3):374-382
35. Heintz A.P.M., Hacker N.F., Berek J.S., Rose T.P., Munoz A.K., Lagasse L.D.: Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 1986; 67:783-788
36. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., Drescher C., Urban N., Hellstrom K.E.: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63 (13):3695-3700
37. Holcomb K., Vucetic Z., Miller M.C., Knapp R.C.: Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011; 205: 358-6
38. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A.: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992; 47:159-66
39. Huhtinen K., Suvitie P., Hiissa J., Junnila J., Huvila J., Kujari H., Setala M., Harkki P., Jalkanen J., Fraser J., Makinen J., Auranen A., Poutanen M., Perheentupa A.: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100 (8):1315-1319
40. Isonishi S., Yasuda M., Takahashi F., Katsumata N., Kimura E., Aoki D., Jobo T., Terauchi F., Tsuda H., Sugiyama T.: Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. J Clin Oncol 2008; 26 (20 suppl): abstr 5506
41. Jaaback K., and Johnson N.: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006; Jan 25, CD005340
42. Jacob F., Meier M., Caduff R. et al.: No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011; 121:487-91
43. Jacobs I., Oram D., Fairbanks J., Turner J., Frost C., Grudzinskas J.: A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. BJOG 1990; 97:922-929
44. Jäger M., Schoberth A., Ruf P., Hess J., Hennig M., Schmalfeldt B., Wimberger P., Ströhlein M., Theissen B., Heiss M.M., Lindhofer H.: Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3). Cancer Res 2012; 72:24-32
45. Jahrbuch der Gesundheitsstatistik. Hrsg.: Statistik Austria, Wien 2007
46. Kauff N.D., Domchek S.M., Friebel T.M., Robson M.E., Lee J., Garber J.E., Isaacs C., Evans D.G., Lynch H., Eeles R.A., Neuhausen S.L., Daly M.B., Matloff E., Blum J.L., Sabbatini P., Barakat R.R., Hudis C., Norton L., Offit K., Rebbeck T.R.: Riskreducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26:1331-1337
47. Kindermann G., Maassen V., Kuhn W.: Laparoscopic preliminary surgery of ovarian malignancies. Experiences from 127 German gynecologic clinics. Geburtsh Frauenheilk 1995; 55:687-694
48. Kristensen G., Perren T., Qian W., Pfisterer J., Ledermann J.A., Joly F., Carey M.S., Beale P.J., Cervantes A., Oza A.M.: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 2011; 29 (Suppl.; Abstr. 5006)
49. Kuhn W., Jänicke F., Hölscher M., Schattenmann G., Schmalfeldt B., Anderl H., Schüle G., Dettmar P., Siewert J.R., Graeff H.: Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtsh Frauenheilk 1993; 53:293-302
50. Kuhn W., Florack G., Roder J., Schmalfeldt B., Rust M., Ulm K., Späthe K., Jänicke F., Siewert J.R., Graeff H.: The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 1998; 8:56-63
51. Lai C.H., Yen T.C., Chang T.C.: Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 2007; 19:37-41
52. Le T., Krepart G.V., Lotocki R.J., Heywood M.S.: Does debulking surgery improve survival in biologically aggressive ovarian cancer? Gynecol Oncol 1998; 67:208-214
53. Luesley D., Lawton F., Blackledge G., Hilton C., Kelly K., Rollason T., Wade-Evans T., Jordan J., Fielding J., Latief T., Chan K.K.: Failure of second look laparotomy to influence survival in epithelial ovarian cancer. Lancet 1988; 10:599-603
54. Maggioni A., Benedetti-Panici P., Dell’Anna T., Landoni F., Lissoni A., Pellegrino A., Rossi R.S., Chiari S., Campagnutta E., Greggi S., Angioli R., Manci N., Calcagno M., Scambia G., Fossati R., Floriani I., Torri V., Grassi R., Mangioni C.: Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006; 95:699-704
55. Markman M., Bundy B., Alberts D., Fowler J., Clark-Pearson D., Carson L., Wadler S., Sickel J.: Phase III Trial of Standard- Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-1007
56. Marth C., Walker J.L., Barakat R.R., Casado A., Gadducci A., Miller B., Odicino F., Pujade-Lauraine E., Sehouli J., Trope C., Wenzel L., Zeimet A.G.: Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007; 109:645-649
57. Mc Guire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M.: Cyclophosphamide and Cisplatin compared with Paclitaxel and Cisplatin compared with Paclitaxel and Cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334:1-6
58. Meta-analysis Group.: Chemotherapy for advanced ovarian cancer. Advanced ovarian cancer Trialists Group. Cochrane Database Syst Rev 2000; 2:CD001418
59. Mizuno M., Kikkawa F., Shibata K., Kajiyama H., Suzuki T., Ino K., Ka M., Mizutani S.: Longterm prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 2003; 65:29-36
60. Mogensen O.: Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44:207-212
61. Molina R., Escudero J.M., Auge J.M., Filella X., Foj L., Torne A., Lejarcegui J., Pahisa J.: HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol 2011; 32 (6): 1087-1095, doi:10.1007/s13277-011-0204-3 [doi]
62. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C.O., Bast R.C. Jr.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008a; 108 (2):402-408
63. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C.O., Bast R.C. Jr.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008b; 108 (2):402-408
64. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., Steinhoff M., Messerlian G., DiSilvestro P., Granai C.O., Bast R.C. Jr.: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008c; 108 (2):402-408, doi:S0090-8258(07)00854-2 [pii];10.1016/j.ygyno.2007.10.017 [doi]
65. Moore R.G., McMeekin D.S., Brown A.K. et al.: A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112:40-6
66. Moore R.G., Jabre-Raughley M., Brown A.K. et al.: Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203:228-6
67. Ness R.B., Grisso J.A., Klapper J., Schlesselman J.J., Silberzweig S., Vergona R., Morgan M., Wheeler J.E.: Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000; 152:233-41
68. Nguyen H.N., Averette H.E., Hoskins W., Sevin B.U., Penalver M., Steren A.: National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993; 72:3007-3011
69. Omura G.A., Brady M.F., Homesley H.D., Yordan E., Major F.J., Buchsbaum H.J., Park R.C.: Long-term follow-up and
prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9:1138-1150
70. Onda T., Yoshikawa H., Yokota H., Yasugi T., Taketani Y.: Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. Cancer 1996; 78:803-808
71. Parmar M.K., Ledermann J.A., Colombo N., du Bois A., Delaloye J.F., Kristensen G.B., Wheeler S., Swart A.M., Qian W., Torri V., Floriani I., Jayson G., Lamont A., Tropé C.; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361:2099-106
72. Pecorelli S., Odicino F., Maisonneuve P. et al.: Carcinoma of the ovary. Annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat 1998; 3:75-102
73. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., Kurzeder C., du Bois A., Sehouli J., Kimmig R., Stähle A., Collinson F., Essapen S., Gourley C., Lortholary A., Selle F., Mirza M.R., Leminen A., Plante M., Stark D., Qian W., Parmar M.K., Oza A.M.; ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484-96
74. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., Wagner U., Stähle A., Stuart G., Kimmig R., Olbricht S., Le T., Emerich J., Kuhn W., Bentley J., Jackisch C., Lück H.J., Rochon J., Zimmermann A.H., Eisenhauer E.; AGO-OVAR; NCIC CTG; EORTC GCG: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 29:4699-707
75. Piver M.S., Baker T.: The potential for optimal (less than or equal to 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol 1986; 24:1-8
76. Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., Gebski V., Heywood M., Vasey P.A., Volgger B., Vergote I., Pignata S., Ferrero A., Sehouli J., Lortholary A., Kristensen G., Jackisch C., Joly F., Brown C., Le Fur N., du Bois A.: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinumsensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28:3323-9
77. Rose P.G., Nerenstone S., Brady M., Clarke-Pearson D., Olt G., Rubin S.C., Moore D.H.: A phase III study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 2002; 21 (Abstr. 802):201a
78. Rosen D.G., Wang L., Atkinson J.N. et al.: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99:267-77
79. Rustin G.J., van der Burg M.E., Griffin C.L., Guthrie D., Lamont A., Jayson G.C., Kristensen G., Mediola C., Coens C., Qian W., Parmar M.K., Swart A.M.; MRC OV05; EORTC 55955 investigators: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376:1155-63
80. Shah C.A., Lowe K.A., Paley P. et al.: Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev 2009; 18:1365-72
81. Scarabelli C., Gallo A., Franceschi S., Campagnutta E., De Piero G., Giorda G., Visentin M.C., Carbone A.: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 2000; 88:389-397
82. Schaner M.E., Ross D.T., Ciaravino G. et al.: Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003; 14:4376-
83. Schilder J.M., Thompson A.M., DePriest P.D., Ueland F.R., Cibull M.L., Kryscio R.J., Modesitt S.C., Lu K.H., Geisler J.P., Higgins
R.V., Magtibay Cohn D.E., Powell M.A., Chu C., Stehman F.B., van Nagell J.: Outcome of reproductive age
women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 2002; 87:1-7
84. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., Thiel R.P.: Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999; 72:93-99
85. Sehouli J., Stengel D., Oskay-Oezcelik G., Zeimet A.G., Sommer H., Klare P., Stauch M., Paulenz A., Camara O., Keil E., Lichtenegger W.: Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008; 26:3176-82
86. Silverberg S.G.: Prognostic significance of pathologic features of ovarian carcinoma. Curr Top Pathol 1989; 78:85-109
87. Silvestrini R., Daidone M.G., Veneroni S., Benini E., Scarfone G., Zanaboni F., Villa A., Presti M., Danese S., Bolis G.: The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. Cancer 1998; 82:159-167
88. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol. 2003; 90:S39-44
89. Strauss H.G., Hemsen A., Karbe I., Lautenschläger C., Persing M., Thomssen C.: Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs 2008; 19:541-545
90. Surwit E., Childers J., Atlas I., Nour M., Hatch K., Hallum A., Alberts D.: Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996; 6:356-361
91. Takano M., Kikuchi Y., Kato M., Yoshikawa T., Kita T.: Bowel perforation associated with bevacizumab therapy in recurrent ovarian cancers without bowel obstruction or bowel involvement. Gan To Kagaku Ryoho 2008; 35:1981-1984
92. Testa A.C., Fruscella E., Ludovisi M., De Vincenzo R., Malaggese M., Corrado G., Basso D., Scambia G., Ferrandia G.: The role of sonographic examination in the follow-up of gynecological neoplasms. Gynecol Oncol 2005; 99:696-703
93. Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., Williams S.: Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993; 71:606-614
94. Timmerman D., Valentin L., Bourne T.H., Collins W.P., Verrelst H., Vergote I.; International Ovarian Tumor Analysis (IOTA) Group: Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 2000; 16:500-5
95. Timmerman D., Testa A.C., Bourne T., Ameye L., Jurkovic D., Van H.C., Paladini D., Van C.B., Vergote I., Van H.S., and Valentin L.: Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008; 31:681-690
96. Trimble E.L., Kosary C.A., Cornelison T.L. et al.: Improved survival for women with ovarian cancer [Abstract]. In Proceedings of the Society for Gynecologic Oncology 1999; Abstract 136
97. Trimbos J.B. Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 2000; 10 (S1): 8-11
98. Valentin L., Ameye L., Testa A., Lecuru F., Bernard J.P., Paladini D., Van H.S., Timmerman D.: Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 2006; 102:41-48
99. Van G.T., Cadron I., Despierre E. et al.: HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011; 104:863-70
100. Van Calster B., Timmerman D., Bourne T., Testa A.C., Van Holsbeke C., Domali E., Jurkovic D., Neven P., Van Huffel S., Valentin L.: Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA 125. J Natl Cancer Inst 2007 Nov 21; 99:1706-14
101. van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., Lacave A.J., Nardi M., Renard J., Pecorelli S.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer; Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. NEJM 1995; 332:629-34
102. Van Holsbeke C., Van C.B., Valentin L., Testa A.C., Ferrazzi E., Dimou I., Lu C., Moerman P., Van H.S., Vergote I., Timmerman D.: External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group. Clin Cancer Res 2007; 13:4440-4447
103. Van Holsbeke C., Domali E., Holland T.K., Achten R., Testa A.C., Valentin L., Jurkovic D., Moerman P., Timmerman D.: Imaging of gynecological disease (3): clinical and ultrasound characteristics of granulosa cell tumors of the ovary. Ultrasound Obstet Gynecol 2008; 31:450-456
104. Vasey P.A.: Management of recurrent epithelial ovarian carcinoma. Aust N Z J Obstet Gynaecol. 2005; 45:269-77.
105. Yancik R.: Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality [Review]. Cancer 1993; 71 (2 Suppl.):517-523
106. Zhang Z., Yu Y., Xu F., Berchuck A., van Haaften-Day C., Havrilesky L.J., de Bruijn H.W., van der Zee A.G., Woolas R.P., Jacobs I.J., Skates S., Chan D.W., Bast R.C. Jr.: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007; 107:526-31
107. Ziółkowska-Seta I., Madry R., Kraszewska E., Szymanska T., Timorek A., Rembiszewska A., Kupryjanczyk J.: TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol 2009; 112:17